Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.

Chani Stossel Maria Raitses-Gurevich Dikla Atias Tamar Beller Yulia Glick Gorman Sharon Halperin Eyal Peer Robert E Denroche Amy Zhang Faiyaz Notta Julie M Wilson Grainne M O'Kane Elina Haimov Talmoud Nora Amison Michael Schvimer Seth J Salpeter Vered Bar Adi Zundelevich Michael Mints Rotem Tal Gal Dinstag Yaron Kinar Yonatan Eliezer Uri Ben-David Nancy S Gavert Ravid Straussman Steven J Gallinger Raanan Berger Talia Golan

Published in: Cancer discovery (2023)

glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development.

Keyphrases